Robert A. Figlin

机构：Cedars-Sinai Medical Center, Palmetto Hematology Oncology, Sinai Health System · ORCID：0000-0002-6323-6075

发表论文 711 篇 · 总被引 53131 次 · h-index 106

代表论文

• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2023 · Journal of Clinical Oncology · 被引 170)
• Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study (2023 · The Lancet Oncology · 被引 105)
• Genetic and biological drivers of prostate cancer disparities in Black men (2023 · Nature Reviews Urology · 被引 31)
• Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study (2025 · The Lancet Oncology · 被引 30)
• LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC) (2023 · Annals of Oncology · 被引 15)
• Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand? (2023 · Journal of Clinical Oncology · 被引 14)